{"title":"Targeting drug-resistant <i>Mycobacterium tuberculosis</i>: an integrated computational approach to identify DprE2 inhibitors.","authors":"S Saxena, A Banerjee, L Guruprasad","doi":"10.1080/1062936X.2025.2506055","DOIUrl":null,"url":null,"abstract":"<p><p><i>Mycobacterium tuberculosis</i> remains one of the leading causes of death from a single infectious agent, posing a major global health challenge. The rise of drug-resistant strains has intensified the need for novel therapeutic agents. Pretomanid and delamanid, two recently developed antitubercular drugs, are bicyclic nitroimidazoles that act as prodrugs, requiring activation by specific mycobacterial enzymes. However, the precise molecular targets of their active metabolites are not fully explained. Recent studies have identified DprE2, an essential enzyme in the biosynthesis of decaprenylphosphoryl-β-D-arabinofuranose (DPA) and arabinogalactan, as a potential target of delamanid. In this study, we applied structure-based pharmacophore modelling to identify potential inhibitors targeting DprE2. High-throughput virtual screening, followed by molecular docking, was used to evaluate binding affinities. ADMET predictions were incorporated to assess drug likeness and pharmacokinetic profiles. Nine promising hits were shortlisted, and their binding stability was further evaluated using 250 ns molecular dynamics simulations. Binding free energy calculations using the MM-GBSA method were then applied to refine the selection, identifying five potent lead molecules. These candidates show strong potential for further development as DprE2 inhibitors, offering a new path in the fight against drug-resistant tuberculosis.</p>","PeriodicalId":21446,"journal":{"name":"SAR and QSAR in Environmental Research","volume":"36 4","pages":"333-363"},"PeriodicalIF":2.3000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"SAR and QSAR in Environmental Research","FirstCategoryId":"93","ListUrlMain":"https://doi.org/10.1080/1062936X.2025.2506055","RegionNum":3,"RegionCategory":"环境科学与生态学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/29 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
引用次数: 0
Abstract
Mycobacterium tuberculosis remains one of the leading causes of death from a single infectious agent, posing a major global health challenge. The rise of drug-resistant strains has intensified the need for novel therapeutic agents. Pretomanid and delamanid, two recently developed antitubercular drugs, are bicyclic nitroimidazoles that act as prodrugs, requiring activation by specific mycobacterial enzymes. However, the precise molecular targets of their active metabolites are not fully explained. Recent studies have identified DprE2, an essential enzyme in the biosynthesis of decaprenylphosphoryl-β-D-arabinofuranose (DPA) and arabinogalactan, as a potential target of delamanid. In this study, we applied structure-based pharmacophore modelling to identify potential inhibitors targeting DprE2. High-throughput virtual screening, followed by molecular docking, was used to evaluate binding affinities. ADMET predictions were incorporated to assess drug likeness and pharmacokinetic profiles. Nine promising hits were shortlisted, and their binding stability was further evaluated using 250 ns molecular dynamics simulations. Binding free energy calculations using the MM-GBSA method were then applied to refine the selection, identifying five potent lead molecules. These candidates show strong potential for further development as DprE2 inhibitors, offering a new path in the fight against drug-resistant tuberculosis.
结核分枝杆菌仍然是单一传染病致人死亡的主要原因之一,对全球健康构成重大挑战。耐药菌株的增加增加了对新型治疗药物的需求。Pretomanid和delamanid是最近开发的两种抗结核药物,是作为前药的双环硝基咪唑,需要被特定的分枝杆菌酶激活。然而,其活性代谢产物的精确分子靶点尚未完全解释。最近的研究发现,DprE2是生物合成十烯丙基磷酸基-β- d -阿拉伯糖铀糖(DPA)和阿拉伯半乳聚糖的必需酶,是delamanid的潜在靶标。在本研究中,我们应用基于结构的药效团模型来确定靶向DprE2的潜在抑制剂。高通量虚拟筛选,随后分子对接,用于评估结合亲和力。ADMET预测被纳入评估药物相似性和药代动力学特征。筛选了9个有希望的靶点,并通过250 ns分子动力学模拟进一步评估了它们的结合稳定性。然后使用MM-GBSA方法计算结合自由能来优化选择,确定了五种有效的铅分子。这些候选药物显示出作为DprE2抑制剂进一步开发的强大潜力,为抗击耐药结核病提供了新的途径。
期刊介绍:
SAR and QSAR in Environmental Research is an international journal welcoming papers on the fundamental and practical aspects of the structure-activity and structure-property relationships in the fields of environmental science, agrochemistry, toxicology, pharmacology and applied chemistry. A unique aspect of the journal is the focus on emerging techniques for the building of SAR and QSAR models in these widely varying fields. The scope of the journal includes, but is not limited to, the topics of topological and physicochemical descriptors, mathematical, statistical and graphical methods for data analysis, computer methods and programs, original applications and comparative studies. In addition to primary scientific papers, the journal contains reviews of books and software and news of conferences. Special issues on topics of current and widespread interest to the SAR and QSAR community will be published from time to time.